A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Completed without a posted recruiting period Show 5 more changesShow less
    • Primary and study completion dates changed from estimate of Jul 2026 to Aug 6, 2026
    • Start date changed from estimate of Jun 2026 to Jun 19, 2026
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 3 of 5 entries
    • Site contact updated
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single-center, single-dose, randomized, open-label, two-period, crossover phase I clinical trial, comparing the bioavailability and safety of the new and old processes of HRS-2189 tablets in healthy subjects.
Trial Details
NCT Number NCT07639905
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions
(from sponsor)		 Malignant Solid Tumor
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov